BMO Capital Markets Reiterates Outperform Rating for Mylan NV (MYL)

Protestors Rally In New York Against Eip Pen Price Gouging Scandal

Mylan N.V. (MYL) now has P/E (Price to Earnings) ratio of 31.68 while the company's industry has 31.4 P/E and the sector P/E is 33.69. Ropes Wealth Advisors LLC acquired a new stake in shares of Mylan N.V. during the first quarter worth about $136,000. Altalis Capital Management Llc bought 9,712 shares as the company's stock rose 10.08% with the market.

Generic drugmakers in the United States were hit by weakening prices in the quarter, and Mylan said it expects mid-single digit generic drug price drops worldwide and high-single digit falls in North America. Kentucky Retirement Systems acquired a new stake in shares of Mylan N.V. during the fourth quarter worth about $1,274,000. Hexavest Inc. raised its stake in shares of Mylan 4.9% in the first quarter. Bank of Nova Scotia increased its stake in Mylan 1.9% in the first quarter. Finally, Wade G W & Inc. increased its stake in Mylan 3.6% in the first quarter. CNA Financial Corp increased its position in Mylan 67.1% in the second quarter. The stock rose 1.81% or $0.58 reaching $32.66 per share. (NYSE:T). Letko Brosseau And Associates accumulated 5.89 million shares or 2.3% of the stock.

Let's have a look at some of the important valuation ratios of the Mylan N.V. (MYL). The firm has a 50-day moving average price of $37.74 and a 200 day moving average price of $39.09. Mylan N.V. also was the target of unusually large options trading on Monday.

North America segment third party net sales of $1.28 billion were down 9%; and up around 4% excluding the decrease in sales of the EpiPen Auto-Injector of approximately $172 million. (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, August 9th.

Adjusted diluted earnings per ordinary share of $1.10 were down 5% over the prior year period. It is positive, as 3 investors sold Mylan N.V. shares while 2 reduced holdings.

15 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 3426.41 million while high and low sale targets are estimated at 3821.1 million and 2913 million respectively. On average, equities research analysts forecast that Mylan N.V. will post $4.86 earnings per share for the current fiscal year. If you are accessing this report on another website, it was copied illegally and reposted in violation of US and global copyright & trademark legislation. The original version of this report can be read at

A number of institutional investors have recently modified their holdings of MYL.

TRADEMARK VIOLATION WARNING: "Somewhat Favorable News Coverage Somewhat Unlikely to Impact Mylan N.V. (NASDAQ:MYL) Stock Price" was originally posted by Rincon Hill News and is owned by of Rincon Hill News.

Mylan N.V. no longer expects to launch generic copies of the blockbuster asthma drug Advair or multiple sclerosis medicine Copaxone this year, a delay which led the specialty pharma to cut its revenue forecasts for 2017.

Cowen and Company restated their hold rating on shares of Mylan N.V. (NASDAQ:MYL) in a research note released on Wednesday. ValuEngine downgraded Mylan N.V. from a "buy" rating to a "hold" rating in a report on Wednesday, June 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company.

In other Mylan N.V. news, insider Anthony Mauro sold 10,000 shares of the business's stock in a transaction dated Friday, June 9th. The Beta for the company stands at 1.29 and its Average True Range (ATR) shows a value of 1.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider now directly owns 140,653 shares in the company, valued at approximately $5,626,120. The disclosure for this sale can be found here.

Drugmakers have cited exactly that FDA shift in explaining why their generics businesses have been hurting, an industry trend that slammed generic drugmakers' and drug distributors' shares late last week.

Related News: